| # |
Company Name
|
Industry Name
|
Latest Price (Rs.)
|
Price Change
Rs (%) |
Market Cap
|
Net Sales
(Rs. Cr.) |
Latest EPS
(Rs.) |
Net Profit
Margin % |
Latest
P/E |
Latest
P/BV |
|---|---|---|---|---|---|---|---|---|---|---|
| Dr. Reddys Labs. | Pharmaceuticals& Drugs | 1,210.9 |
-13.05 (-1.07%) |
Mid Cap | 33,700 | 50.3 | 11.44 | 24.4 | 2.7 | |
| Lupin | Pharmaceuticals& Drugs | 2,442.1 |
-57.95 (-2.32%) |
Mid Cap | 27,958 | 116.6 | 18.82 | 21.4 | 5.1 | |
| Zydus Lifesciences | Pharmaceuticals& Drugs | 1,142.8 |
-10.75 (-0.93%) |
Mid Cap | 27,148 | 50.5 | 16.54 | 22.8 | 4.4 | |
| Glenmark Pharma. | Pharmaceuticals& Drugs | 2,235.9 |
-51.7 (-2.26%) |
Mid Cap | 13,322 | 48.3 | 9.67 | 47.4 | 6.1 | |
| Aurobindo Pharma | Pharmaceuticals& Drugs | 1,534.1 |
-14.05 (-0.91%) |
Mid Cap | 10,933 | 42 | 15.17 | 36.9 | 3.9 | |
| Mankind Pharma | Pharmaceuticals& Drugs | 2,491.5 |
-53.55 (-2.1%) |
Mid Cap | 10,421 | 49.3 | 19.97 | 51.6 | 6.4 | |
| Alkem Laboratories | Pharmaceuticals& Drugs | 5,552.9 |
-150.6 (-2.64%) |
Mid Cap | 8,813 | 182.8 | 23.18 | 31.2 | 4.9 | |
| Max Healthcare Inst. | Hospital &HealthcareServices | 1,089.7 |
-8.95 (-0.81%) |
Mid Cap | 8,373 | 14.8 | 17.65 | 74.1 | 10.1 | |
| Ipca Laboratories | Pharmaceuticals& Drugs | 1,904.8 |
13.5 (0.71%) |
Mid Cap | 7,289 | 44.6 | 16.38 | 42.4 | 6 | |
| Laurus Labs | Pharmaceuticals& Drugs | 1,529.7 |
-27.95 (-1.79%) |
Mid Cap | 6,813 | 16.5 | 12.82 | 94.7 | 16 | |
| Abbott India | Pharmaceuticals& Drugs | 28,013.6 |
132.6 (0.48%) |
Mid Cap | 6,409 | 730.4 | 22.1 | 38.2 | 12.4 | |
| Narayana Hrudayalay. | Hospital &HealthcareServices | 2,027.6 |
-2.8 (-0.14%) |
Mid Cap | 5,483 | 39.4 | 14.35 | 51.5 | 9.1 | |
| Ajanta Pharma | Pharmaceuticals& Drugs | 3,416.8 |
-31.65 (-0.92%) |
Mid Cap | 5,453 | 84.5 | 19.33 | 40.8 | 9.5 | |
| Aster DM Quality | Hospital &HealthcareServices | 820 |
8.55 (1.05%) |
Mid Cap | 4,138 | 4.5 | 8.01 | 182.2 | 14.4 | |
| Lenskart Solutions | MedicalEquipment/Supplies/Accessories | 536.9 |
2.25 (0.42%) |
Mid Cap | 4,039 | 2.7 | 4.65 | 195.3 | 10.2 | |
| Glaxosmithkline Phar | Pharmaceuticals& Drugs | 2,455.1 |
-51.65 (-2.06%) |
Mid Cap | 3,822 | 61.2 | 25.36 | 41 | 18.6 | |
| Biocon | Pharmaceuticals& Drugs | 437 |
-3.7 (-0.84%) |
Mid Cap | 2,346 | 0.2 | 5.85 | 1,930.7 | 2.7 | |
| Anthem Biosciences | Pharmaceuticals& Drugs | 776.1 |
17.25 (2.27%) |
Mid Cap | 2,089 | 11.9 | 30.95 | 63.8 | 13.6 | |
| Fortis Healthcare | Hospital &HealthcareServices | 952 |
-11.5 (-1.19%) |
Mid Cap | 1,446 | 3.1 | 9.99 | 315.8 | 7.9 |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: